Financial Performance - FY25 revenue reached $21.84 billion, with adjusted FXN growth of 7.7% and organic growth of 2.9%[16,44] - Adjusted diluted EPS for FY25 was $14.40, a 9.6% year-over-year increase[16] - Adjusted operating margin for FY25 was 25.0%, an increase of 80 bps year-over-year[16] - The company returned $2.2 billion to shareholders through share repurchases and dividends[16,48] - Free cash flow for FY25 was $2.67 billion, a 14% decrease compared to FY24's $3.119 billion[47] Segment Performance (Q4 FY25) - BD Medical segment revenue was $3.155 billion, with a 9.9% FXN increase[34] - BD Life Sciences segment revenue was $1.368 billion, with a 0.3% FXN increase[36] - BD Interventional segment revenue was $1.367 billion, with a 7.5% FXN increase[39] FY26 Guidance - The company expects low single-digit revenue growth (FXN) for FY26, including a ~90 bps FX tailwind[53] - Adjusted diluted EPS for FY26 is projected to be between $14.75 and $15.05, a 2.4% to 4.5% increase[53]